---
title: "Shionogi & Co: Strong ROE and growth-focused strategies drive value, supported by robust governance and IR"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290661670.md"
description: "High drug discovery capabilities and a robust royalty business drive strong ROE, while strategies focus on improving PER and PBR through growth investments, business model evolution, and enhanced communication. Governance, sustainability, and proactive investor engagement underpin long-term value creation.Original document: Shionogi & Co., Ltd. [4507] Slides Release — Jun. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-24T07:57:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290661670.md)
  - [en](https://longbridge.com/en/news/290661670.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290661670.md)
generator: "portal-rs"
---

# Shionogi & Co: Strong ROE and growth-focused strategies drive value, supported by robust governance and IR

High drug discovery capabilities and a robust royalty business drive strong ROE, while strategies focus on improving PER and PBR through growth investments, business model evolution, and enhanced communication. Governance, sustainability, and proactive investor engagement underpin long-term value creation.

Original document: Shionogi & Co., Ltd. \[4507\] Slides Release — Jun. 24 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [4507.JP](https://longbridge.com/en/quote/4507.JP.md)
- [SGIOY.US](https://longbridge.com/en/quote/SGIOY.US.md)

## Related News & Research

- [Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout](https://longbridge.com/en/news/301030270.md)
- [Shionogi (TSE:4507) Wins New Drug Approvals On Questions Over Whether The Value Case Still Holds](https://longbridge.com/en/news/299369411.md)
- [Short Interest in Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Grows By 797.8%](https://longbridge.com/en/news/298662387.md)
- [Shionogi starts omnichannel campaign for COVID-19 pill Xocova](https://longbridge.com/en/news/299054121.md)
- [Shionogi presents new Phase 3 SCORPIO-PEP subpopulation data on COVID-19 antiviral XOCOVA at IDWeek 2026](https://longbridge.com/en/news/298458503.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**